Evidence map›Paper›PMID 39672820›Full record

ArticleScientific reports2024

Cheminformatics-based design and biomedical applications of a new Hydroxyphenylcalix[4] resorcinarene as anti-cancer agent.

S F Alshahateet, R M Altarawneh, S A Al-Trawneh, Y M Al-Saraireh, W M Al-Tawarh, K R Abuawad, Y M Abuhalaweh, M Zerrouk, A Ait Mansour, R Salghi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Spherical Amides withMolecules (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

S F AlshahateetDepartment of Chemistry, Faculty of Science, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan. s_alshahateet@mutah.edu.jo.
R M AltarawnehDepartment of Chemistry, Faculty of Science, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
S A Al-TrawnehDepartment of Chemistry, Faculty of Science, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
Y M Al-SarairehDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
W M Al-TawarhDepartment of Chemistry, Faculty of Science, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
K R AbuawadDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
Y M AbuhalawehDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak, 61710, Jordan.
M ZerroukEngineering Laboratory of Organometallic, Molecular Materials and Environment, Faculty of Sciences, Sidi Mohammed Ben Abdellah University, 30000, Fez, Morocco.
A Ait MansourLaboratory of Applied Chemistry and Environment, ENSA, University Ibn Zohr, P.O. Box 1136, 80000, Agadir, Morocco.
R SalghiLaboratory of Applied Chemistry and Environment, ENSA, University Ibn Zohr, P.O. Box 1136, 80000, Agadir, Morocco.
B HammoutiEuromed Research Center, Euromed Polytechnic School, Euromed University of Fes, UEMF, 30030, Fez, Morocco.
M MerzoukiLaboratory of Applied Chemistry and Environment, Department of Chemistry, Faculty of Sciences, Mohammed 1st University, Oujda, Morocco.
R SabbahiResearch Team in Science and Technology, Higher School of Technology, Ibn Zohr University, P.O. Box 3007, Laayoune, Morocco.
L RhaziInstitut Polytechnique UniLaSalle, Université d'Artois, ULR 7519, 19 Rue Pierre Waguet, BP 30313, 60026, Beauvais, France.
Mohammed M AlanaziDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia. mmalanazi@ksu.edu.sa.
K AzzaouiEngineering Laboratory of Organometallic, Molecular Materials and Environment, Faculty of Sciences, Sidi Mohammed Ben Abdellah University, 30000, Fez, Morocco.

Funding

Deanship of Scientific Research, King Saud University RSPD2024R628Deanship of Scientific Research, Mutah University Decision no. 766/2023
6 · The paper itself

Abstract

The distinct conformational characteristics, functionality, affordability, low toxicity, and usefulness make calixarene-based compounds a promising treatment option for cancer. The aim of the present study is to synthesize a new calixarene-based compound and assess of its anticancer potential on some human cancer cells. The synthesized C-4-Hydroxyphenylcalix[4] resorcinarene (HPCR) was characterized by several spectroscopic techniques such as 1HNMR, 13CNMR, and X-ray crystallographic analysis to confirm its purity and identity. IC

Indexed as

Antineoplastic AgentsCalixarenesCheminformaticsMolecular Docking SimulationPhenylalanineA549 CellsCarbon-13 Magnetic Resonance SpectroscopyCell Line, TumorCrystallography, X-RayDrug DesignFibroblastsHumansInhibitory Concentration 50Antineoplastic AgentsCalixarenesPhenylalanineresorcinareneAnti-cancer agentAnti-proliferative activityCalix[n]arenesMolecular dockingMTT assay

Identifiers

PMID39672820
PMCPMC11645408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.